Unresectable Melanoma clinical trials

Explore recruiting unresectable melanoma clinical trials.

Recruiting unresectable melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Unresectable Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Czechia, Germany, Belgium, Spain, Austria, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Spain, Italy, France, Belgium, Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab vs Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Romania, Finland, Austria, Italy, Germany, Belgium +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases

Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor

France, Spain, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Unresectable Melanoma trials by city

Unresectable Melanoma in Toronto Unresectable Melanoma in Vancouver Unresectable Melanoma in Montreal Unresectable Melanoma in Calgary Unresectable Melanoma in Edmonton Unresectable Melanoma in Ottawa Unresectable Melanoma in Winnipeg Unresectable Melanoma in Quebec City Unresectable Melanoma in Hamilton Unresectable Melanoma in Kitchener Unresectable Melanoma in London Unresectable Melanoma in Halifax Unresectable Melanoma in New York Unresectable Melanoma in Los Angeles Unresectable Melanoma in Chicago Unresectable Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease